Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Summary

This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.

Timeline

Start

2021-07-23

Primary completion

2025-06-10

Completion

2027-05-31

Outcome

Met primary endpoint

release “在R/M CC一线治疗中，卡瑞利珠单抗联合法米替尼的去化疗方案与含铂类化疗（联合或不联合贝伐珠单抗）相比，显著延长了PFS和OS，达到了中期分析的双重主要终点。” hengrui.com ↗

Drugs

Indications